REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER) (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, will showcase the ...
Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...
Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, ...
REDWOOD CITY - Seer, Inc. (NASDAQ:SEER) will present its proteomics technology at the 2026 U.S. Human Proteome Organization Annual Conference taking place February 21-25 in St. Louis, according to a ...
Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, ...
Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer ...
At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results